导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.46% | 934/4773 |
| 近一周 | 0.34% | 631/5465 |
| 近一月 | -9.21% | 5184/5421 |
| 近一季 | 22.20% | 61/5231 |
| 近半年 | 9.42% | 614/4920 |
| 近一年 | -7.97% | 3289/4394 |
| 近两年 | 61.29% | 1207/2954 |
| 近三年 | 15.18% | 1635/2253 |
| 成立以来 | -4.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.09% 1369/4961 |
0.81% 3123/5312 |
- - |
- - |
| 2025 | 27.95% 1522/4813 |
15.43% 174/3635 |
3.70% 961/4076 |
23.35% 1550/4524 |
-13.34% 4295/4813 |
| 2024 | -16.66% 2507/3463 |
-15.19% 2539/2808 |
-13.02% 2621/3014 |
23.56% 381/3129 |
-8.57% 2868/3463 |
| 2023 | -14.47% 1604/2656 |
0.92% 1673/2280 |
-13.32% 2209/2385 |
1.47% 305/2515 |
-3.64% 751/2655 |
| 2022 | -28.21% 1540/2207 |
-9.32% 318/1919 |
-7.44% 1891/2016 |
-20.91% 1886/2113 |
8.13% 273/2208 |
| 2021 | -15.88% 1161/1822 |
-2.71% 694/1255 |
12.33% 338/1330 |
-17.17% 1408/1466 |
-7.07% 1563/1822 |
| 2020 | 67.00% 87/1250 |
10.61% 17/1028 |
36.86% 15/1067 |
6.30% 858/1164 |
3.78% 889/1184 |
| 2019 | 56.14% 68/1092 |
33.76% 131/754 |
-5.36% 465/804 |
13.36% 24/850 |
8.80% 287/918 |
| 2018 | -29.99% 461/834 |
- - |
- - |
- - |
-17.36% 648/691 |
| 2017 | -5.18% 509/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 汇添富中证精准医疗指数(LOF)A VS. 长安沪深300非周期A(740101) |